Quest Diagnostics (DGX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Quest Diagnostics (DGX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

152.81

-0.46 (-0.30%)

At close: Jan 14, 2025, 3:59 PM

undefined% (undefined)

Bid	149.13
Market Cap	17.06B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	7.44
PE Ratio (ttm)	20.54
Forward PE	n/a
Analyst	Hold

Ask	171
Volume	456,833
Avg. Volume (20D)	840,688
Open	153.05
Previous Close	153.27
Day's Range	150.47 - 153.12
52-Week Range	123.04 - 165.32
Beta	undefined

About DGX

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPat...

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Dec 17, 1996

Employees 50,000

Stock Exchange NYSE

Ticker Symbol DGX

Website https://www.questdiagnostics.com

Analyst Forecast

According to 13 analyst ratings, the average rating for DGX stock is "Hold." The 12-month stock price forecast is $172, which is an increase of 12.56% from the latest price.

Buy 53.85%

Hold 46.15%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Quest Diagnostics is scheduled to release its earnings on Jan 30, 2025, before market opens.
Analysts project revenue of $2.58B, reflecting a 12.76% YoY growth and earnings per share of 2.19, making a 1.86% increase YoY.

Why Price Moved

2 months ago · Source

+6.85%

Quest Diagnostics shares are trading higher after ... Unlock content with Pro Subscription

5 months ago · Source

-4.34%

Quest Diagnostics shares are trading lower. The company reported Q2 financial results.

News

1 week ago · zacks.com

Why Quest Diagnostics (DGX) is Poised to Beat Earnings Estimates Again

Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2 weeks ago · zacks.com

Should You Hold Quest Diagnostics Stock in Your Portfolio Now?

DGX's strength in the base business and the robust adoption of Advanced Diagnostics services bode well.

1 month ago · zacks.com

New Health Coaching Service on questhealth.com Set to Boost DGX Stock

Quest Diagnostics introduces Health Coaching on questhealth.com, helping individuals take control of their health.

1 month ago · zacks.com

Quest Diagnostics (DGX) Up 2.7% Since Last Earnings Report: Can It Continue?

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?

2 months ago · businesswire.com

Augurex Life Sciences and Quest Diagnostics Collaborate to Improve Rheumatoid Arthritis Diagnosis and Management

VANCOUVER, British Columbia--(BUSINESS WIRE)-- #AxialSpondyloarthritis--Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that it has formed a nonexclusi...

2 months ago · zacks.com

All You Need to Know About Quest Diagnostics (DGX) Rating Upgrade to Buy

Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · zacks.com

Is Quest Diagnostics Stock a Smart Addition to Your Portfolio Now?

DGX exhibits strength in its base business. Increasing utilization of the Advanced Diagnostics offering is another positive.

2 months ago · zacks.com

DGX vs. PNTG: Which Stock Is the Better Value Option?

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Quest Diagnostics (DGX) and The Pennant Group, Inc. (PNTG). But which of these two companies is the bes...

2 months ago · zacks.com

Here's Why You Should Retain DGX Stock in Your Portfolio Now

Investors feel optimistic about Quest Diagnostics' strength in Advanced Diagnostics. Robust base business volumes are also encouraging.

2 months ago · zacks.com

Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

2 months ago · seekingalpha.com

Quest Diagnostics Has Massive Secular Tailwinds And A Strong Base

Quest Diagnostics benefits from an aging population, driving increased lab testing volumes, particularly in genetic testing, and offers a 2.0% dividend yield. DGX's M&A strategy, including the LifeLab...

2 months ago · seekingalpha.com

Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat

Quest Diagnostics reported strong Q3 earnings, with an 8.5% revenue increase and a 3.6% rise in diluted EPS, beating Street expectations. The company raised its 2024 revenue guidance and expects signi...

2 months ago · zacks.com

DGX or PNTG: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Quest Diagnostics (DGX) or The Pennant Group, Inc. (PNTG). But which of these two comp...

2 months ago · zacks.com

4 Stocks to Buy in an Evolving Outpatient Home Health Industry

Dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, AMED and ADUS are well-poised ...

2 months ago · reuters.com

US lab operator Quest Diagnostics to launch bird flu test at end of October

Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and Prevention (CDC) gave it contracts to supp...

2 months ago · youtube.com

Overlooked Stock: DGX

One of the biggest earnings movers from Tuesday: Quest Diagnostics (DGX). The lab & testing company beat on the top-and-bottom line in its 3Q report, as shares surged to multi-month highs.

2 months ago · seekingalpha.com

Quest Diagnostics (DGX) Q3 2024 Earnings Call Transcript

Quest Diagnostics Incorporated (NYSE:DGX ) Q3 2024 Earnings Conference Call October 22, 2023 8:30 AM ET Company Participants Jim Davis - President, Chief Executive Officer Sam Samad - Executive Vice P...

2 months ago · benzinga.com

Quest Diagnostics CEO Touts 'New Customer Wins' In Q3, Expects Earnings Growth In 2025

Quest Diagnostics Inc DGX posted third-quarter adjusted earnings per share of $2.30, beating the consensus of $2.26.

2 months ago · zacks.com

DGX Stock Rises on Q3 Earnings and Revenue Beat, 2024 Sales View Up

Quest Diagnostics' third-quarter 2024 performance reflects impressive DIS business growth and the benefits of new acquisitions.

2 months ago · zacks.com

Quest Diagnostics (DGX) Beats Q3 Earnings and Revenue Estimates

Quest Diagnostics (DGX) came out with quarterly earnings of $2.30 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $2.22 per share a year ago.

Load More News